177 related articles for article (PubMed ID: 36009263)
1. Decreased Levels of GSH Are Associated with Platinum Resistance in High-Grade Serous Ovarian Cancer.
Criscuolo D; Avolio R; Parri M; Romano S; Chiarugi P; Matassa DS; Esposito F
Antioxidants (Basel); 2022 Aug; 11(8):. PubMed ID: 36009263
[TBL] [Abstract][Full Text] [Related]
2. Auranofin Induces Lethality Driven by Reactive Oxygen Species in High-Grade Serous Ovarian Cancer Cells.
Abdalbari FH; Martinez-Jaramillo E; Forgie BN; Tran E; Zorychta E; Goyeneche AA; Sabri S; Telleria CM
Cancers (Basel); 2023 Oct; 15(21):. PubMed ID: 37958311
[TBL] [Abstract][Full Text] [Related]
3. Checkpoint kinase 2 (Chk2) supports sensitivity to platinum-based treatment in high grade serous ovarian cancer.
Alkema NG; Tomar T; van der Zee AG; Everts M; Meersma GJ; Hollema H; de Jong S; van Vugt MA; Wisman GB
Gynecol Oncol; 2014 Jun; 133(3):591-8. PubMed ID: 24657486
[TBL] [Abstract][Full Text] [Related]
4. Aurora Kinase A expression predicts platinum-resistance and adverse outcome in high-grade serous ovarian carcinoma patients.
Mignogna C; Staropoli N; Botta C; De Marco C; Rizzuto A; Morelli M; Di Cello A; Franco R; Camastra C; Presta I; Malara N; Salvino A; Tassone P; Tagliaferri P; Barni T; Donato G; Di Vito A
J Ovarian Res; 2016 May; 9(1):31. PubMed ID: 27209210
[TBL] [Abstract][Full Text] [Related]
5. Studying platinum sensitivity and resistance in high-grade serous ovarian cancer: Different models for different questions.
Alkema NG; Wisman GB; van der Zee AG; van Vugt MA; de Jong S
Drug Resist Updat; 2016 Jan; 24():55-69. PubMed ID: 26830315
[TBL] [Abstract][Full Text] [Related]
6. Interferon regulatory factor 1 is an independent predictor of platinum resistance and survival in high-grade serous ovarian carcinoma.
Cohen S; Mosig R; Moshier E; Pereira E; Rahaman J; Prasad-Hayes M; Halpert R; Billaud JN; Dottino P; Martignetti JA
Gynecol Oncol; 2014 Sep; 134(3):591-8. PubMed ID: 24995581
[TBL] [Abstract][Full Text] [Related]
7. Critical role of Wnt/β-catenin signaling in driving epithelial ovarian cancer platinum resistance.
Nagaraj AB; Joseph P; Kovalenko O; Singh S; Armstrong A; Redline R; Resnick K; Zanotti K; Waggoner S; DiFeo A
Oncotarget; 2015 Sep; 6(27):23720-34. PubMed ID: 26125441
[TBL] [Abstract][Full Text] [Related]
8. Single-cell analysis of a high-grade serous ovarian cancer cell line reveals transcriptomic changes and cell subpopulations sensitive to epigenetic combination treatment.
Sriramkumar S; Metcalfe TX; Lai T; Zong X; Fang F; O'Hagan HM; Nephew KP
PLoS One; 2022; 17(8):e0271584. PubMed ID: 35921335
[TBL] [Abstract][Full Text] [Related]
9. Bioinformatic profiling identifies a platinum-resistant-related risk signature for ovarian cancer.
Wu C; He L; Wei Q; Li Q; Jiang L; Zhao L; Wang C; Li J; Wei M
Cancer Med; 2020 Feb; 9(3):1242-1253. PubMed ID: 31856408
[TBL] [Abstract][Full Text] [Related]
10. Promoter Methylation of the
Li XF; Sun HY; Hua T; Zhang HB; Tian YJ; Li Y; Kang S
Front Oncol; 2021; 11():659254. PubMed ID: 34268111
[TBL] [Abstract][Full Text] [Related]
11. Downregulation of LINC00515 in high-grade serous ovarian cancer and its relationship with platinum resistance.
Ni MW; Zhou J; Zhang YL; Zhou GM; Zhang SJ; Feng JG; Xu Q; Zhou Y; Mou HZ; Zheng ZG
Biomark Med; 2019 May; 13(7):535-543. PubMed ID: 31140829
[No Abstract] [Full Text] [Related]
12. Pathogenic Heteroplasmic Somatic Mitochondrial DNA Mutation Confers Platinum-Resistance and Recurrence of High-Grade Serous Ovarian Cancer.
Ni J; Wang Y; Cheng X; Teng F; Wang C; Han S; Chen X; Guo W
Cancer Manag Res; 2020; 12():11085-11093. PubMed ID: 33173341
[TBL] [Abstract][Full Text] [Related]
13. Methylomic Signatures of High Grade Serous Ovarian Cancer.
Cardenas H; Fang F; Jiang G; Perkins SM; Zhang C; Emerson RE; Hutchins G; Keer HN; Liu Y; Matei D; Nephew K
Epigenetics; 2021 Nov; 16(11):1201-1216. PubMed ID: 33289590
[TBL] [Abstract][Full Text] [Related]
14. Hyper-phosphorylation of Sequestosome-1 Distinguishes Resistance to Cisplatin in Patient Derived High Grade Serous Ovarian Cancer Cells.
Nguyen EV; Huhtinen K; Goo YA; Kaipio K; Andersson N; Rantanen V; Hynninen J; Lahesmaa R; Carpen O; Goodlett DR
Mol Cell Proteomics; 2017 Jul; 16(7):1377-1392. PubMed ID: 28455291
[TBL] [Abstract][Full Text] [Related]
15. Effect of buthionine sulfoximine on PtII and PtIV drug accumulation and the formation of glutathione conjugates in human ovarian-carcinoma cell lines.
Mistry P; Loh SY; Kelland LR; Harrap KR
Int J Cancer; 1993 Nov; 55(5):848-56. PubMed ID: 8244583
[TBL] [Abstract][Full Text] [Related]
16. Serum CA125 and ascites leptin level ratio predicts baseline clinical resistance to first-line platinum-based treatment and poor prognosis in patients with high grade serous ovarian cancer.
Matte I; Garde-Granger P; Bessette P; Piché A
Am J Cancer Res; 2019; 9(1):160-170. PubMed ID: 30755819
[TBL] [Abstract][Full Text] [Related]
17. Activated Integrated Stress Response Induced by Salubrinal Promotes Cisplatin Resistance in Human Gastric Cancer Cells via Enhanced xCT Expression and Glutathione Biosynthesis.
Wang SF; Wung CH; Chen MS; Chen CF; Yin PH; Yeh TS; Chang YL; Chou YC; Hung HH; Lee HC
Int J Mol Sci; 2018 Oct; 19(11):. PubMed ID: 30380689
[TBL] [Abstract][Full Text] [Related]
18. CDK4/6 inhibition as maintenance and combination therapy for high grade serous ovarian cancer.
Iyengar M; O'Hayer P; Cole A; Sebastian T; Yang K; Coffman L; Buckanovich RJ
Oncotarget; 2018 Mar; 9(21):15658-15672. PubMed ID: 29644000
[TBL] [Abstract][Full Text] [Related]
19. Nelfinavir Induces Cytotoxicity towards High-Grade Serous Ovarian Cancer Cells, Involving Induction of the Unfolded Protein Response, Modulation of Protein Synthesis, DNA Damage, Lysosomal Impairment, and Potentiation of Toxicity Caused by Proteasome Inhibition.
Subeha MR; Goyeneche AA; Bustamante P; Lisio MA; Burnier JV; Telleria CM
Cancers (Basel); 2021 Dec; 14(1):. PubMed ID: 35008264
[TBL] [Abstract][Full Text] [Related]
20. High Serpin Family A Member 10 Expression Confers Platinum Sensitivity and Is Associated With Survival Benefit in High-Grade Serous Ovarian Cancer: Based on Quantitative Proteomic Analysis.
Guo W; He X; Ni J; Ma L; Cheng X; Wang C; Chen X; Wang Y
Front Oncol; 2021; 11():761960. PubMed ID: 34888242
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
